Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 26,205

Document Document Title
WO/2020/013307A1
Provided is, inter alia, a method for producing a concentrated yogurt for promoting muscle synthesis. A method for producing a concentrated yogurt, in which a yogurt is concentrated, is used to obtain a yogurt by fermenting a prepared yo...  
WO/2019/232548A3
The present disclosure relates to compositions comprising an antisense RNA seqeunce comprising a region of complementarity that is substantially complementary to an miRNA. Pharmaceutical compositions comprising the antisense RNA molecule...  
WO/2020/009147A1
[Problem] To provide a stem cell filtrate formulation which is useful for hair regeneration, the alleviation of pain caused by interosseous joint disease such as osteoarthrosis and articular rheumatism, and the treatment of said disease,...  
WO/2020/009444A1
The present invention relates to a gene and cell therapy product using a cell fusion technology and a use thereof. More particularly, cells which overexpress hemagglutinin neuraminidase (HN) and F (fusion) protein were found to have an i...  
WO/2020/004594A1
This prophylactic or therapeutic agent for spinal muscular atrophy includes a compound represented by formula (I) or a salt thereof (in the formula: W1, W2, and W3 are each independently selected from the group consisting of C-R2, C-R3, ...  
WO/2020/004675A1
The present invention relates to a composition containing an antisense oligonucleotide and a use thereof for the treatment of Duchenne muscular dystrophy. The present invention, specifically, relates to the composition effective for the ...  
WO/2020/004014A1
The present invention provides: a culture medium and a culture medium additive which are for myogenic differentiation promotion and which contain ergothioneine, ascorbic acid 2-glucoside, ascorbic acid, or a combination thereof; a kit; a...  
WO/2020/004568A1
The present invention provides a novel means for promoting equol production in human intestines or a novel means for amelioration of premenstrual syndrome, which is related to such equol production, and for improving skin condition chang...  
WO/2020/004709A1
The present invention relates to a pharmaceutical composition comprising a combination of Erigeron annuus flower essential oil and botulinum toxin (Botox) for prevention or treatment of neuromuscular disease and a pharma-beauty compositi...  
WO/2020/002715A1
The present invention relates to a pharmaceutical combination for use in the treatment, prevention and/or stabilization of age-related diseases and/or degenerative diseases. In particular, said pharmaceutical combination comprises a bigu...  
WO/2019/246225A1
This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle functi...  
WO/2019/246125A1
Products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies are provided. In the methods, a protein including a linker domain, such as the heparin-binding domain of Heparin-Binding Epidermal Growth F...  
WO/2019/242687A1
The present invention discloses a 1,3-dioxane-4,6-dione compound, and a preparation method, a pharmaceutical composition, and an application thereof. The structure of the compound is represented by formula I, and the definition of each s...  
WO/2019/241850A1
The present invention relates to substituted sulfonyl hydrazides that have the ability to inhibit lysine biosynthesis via the diaminopimelate pathway in certain organisms. As a result of this activity these compounds can be used in appli...  
WO/2019/242039A1
Disclosed is a method for preparing a rocuronium bromide injection with a low impurity level, wherein the method makes use of the means of reducing the temperature of the formulation solution and nitrogen aeration, controlling the endoto...  
WO/2019/241634A1
This document provides methods and materials involved in treating congenital disorders of glycosylation (CDGs). For example, methods for using a composition including one or more uridine diphosphate (UDP) - sugars to treat a mammal (e.g....  
WO/2019/237185A1
The present disclosure relates to compounds comprising β-hydroxybutyric acid, and a weakly basic polymer. The disclosure also includes methods for inducing nutritional ketosis comprising administering the compounds or compositions compr...  
WO/2019/241633A1
Disclosed herein are methods of treating or preventing a disease caused by nonsense mutations, or ameliorating one or more symptoms associated therewith, that involve administering to a patient in need thereof a therapeutically or prophy...  
WO/2018/076060A9
Methods and compositions for producing mature myotubes are provided herein. In some instances, the method involves contacting a myoblast in an in vitro culture with a compound, wherein the contacting the myoblast in the in vitro culture ...  
WO/2019/240126A1
[Problem] To provide a pharmaceutical composition that promotes the production of monoamine neurotransmitters in a living body having blood and cerebral fluid. [Solution] This pharmaceutical composition containing mesenchymal stem cells ...  
WO/2019/234664A1
The present disclosure relates to a method of treating or preventing mitochondrial diseases by administering 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methy l]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in nee...  
WO/2019/235569A1
The present invention addresses the problem of providing: a novel kinase inhibitor and others; and a therapeutic agent for a disease, a drug discovery screening method and others, each utilizing the inhibitor and others. A compound repre...  
WO/2019/236082A1
Provided herein are stem-cell based therapies for the treatment of neurodegenerative diseases and CNS disorder such as Huntington's disease. The therapy improved motor deficits and rescued synaptic alterations. The cells were shown to be...  
WO/2019/235597A1
Provided is a compound which has little adverse side effects and a mild action and can be used for the activation of autophagy. An autophagy activating agent which contains S1PC or a salt thereof as an active ingredient.  
WO/2019/234237A1
The present application relates to compounds of formula (1) and their use as medicament, in particular for the treatment of a medical condition associated with defective PI3K signalling.  
WO/2019/230957A1
The present invention addresses the problem of providing a novel composition for accelerating muscle repair. Cells and/or a culture of a bacterium belonging to Lactobacillus is used as an active ingredient, making it possible to provide ...  
WO/2019/230558A1
Provided is an anti-inflammatory drug that is more effective and has fewer side effects in comparison to NSAIDs or steroidal anti-inflammatory drugs. Specifically, a therapeutic agent for inflammatory conditions that contains, as an acti...  
WO/2019/231150A1
The present invention relates to a composition comprising Aster sphathulifolius Maxim extract for preventing, improving, or treating muscular diseases and for improving muscular functions. The Aster sphathulifolius Maxim extract accordin...  
WO/2019/230207A1
A method for producing an oil-in-water type emulsion composition, comprising: step A of subjecting a material to be emulsified to an emulsification treatment by applying a pressure of 20 to 350 MPa inclusive to produce an emulsion, where...  
WO/2019/230907A1
One aspect of the present invention provides an anti-obesity agent, an anti-dementia agent, a deodorant, an anti-aging agent, an anti-glycation agent, an anti-type I allergy agent, a hypotensive agent, a flavor improving agent, a muscle ...  
WO/2019/226015A1
The present invention relates to a composition for promoting myogenesis, containing, as an active ingredient, a processed ginseng extract in which a trace amount of a ginsenoside ingredient is increased. It has been ascertained that the ...  
WO/2019/226858A1
Disclosed herein are methods and compositions for the treatment of muscle contractures. In particular, the disclosed methods and compositions may be used to improve longitudinal muscle growth in individuals having muscle contractures, fo...  
WO/2019/226835A1
The present disclosure relates to compounds and methods for modulating the expression of dmpk, atxnl, atxn2, atxn.3, cacnala, atxn7, ppp2r2br tbp, htt, jph3r ar, or atnl and treating diseases and conditions in which dmpk, atxnl, atxn2, a...  
WO/2019/225625A1
The present invention pertains to a compound represented by general formula (I) [the symbols in the formula are as described in the specification] or a pharmacologically acceptable salt thereof, and to a pharmaceutical composition contai...  
WO/2019/222146A1
In some embodiments of the invention, inventive compounds (e.g., Formula (I), (IA), (II), and (III), and urolithin derivatives) are disclosed. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inve...  
WO/2019/222354A1
The disclosure features compositions and methods for the treatment of disorders associated with improper ribonucleic acid (RNA) splicing, including disorders characterized by nuclear retention of RNA transcripts containing aberrantly exp...  
WO/2019/215317A1
The present invention relates to non-steroidal mineralocorticoid receptor antagonists (MR Antagonists, MRAs) alone or preferably in combination with sGC stimulators and/or sGC activators, for use in the prevention and/or treatment of mus...  
WO/2019/215470A1
The present invention relates to the use of Guanabenz or derivates thereof for the treatment of type I IFN-dependent pathologies.The inventors investigate here how pharmacological interference with the eIF2α-P pathway can be beneficial ...  
WO/2019/217757A1
The present disclosure relates to compounds and methods for modulating the expression ofc9orf72 (brain expressed, associated with NEDD4) and treating diseases and conditions in whichc9orf72plays an active role. The compound can be a tran...  
WO/2019/215090A1
The present invention concerns a method of generating a population of skeletal muscle derived human muscle precursor cells. For this purpose, a specialized FBS-free cell growth medium is used. The invention further concerns a composition...  
WO/2019/211734A1
The present invention relates to the field of adult stem cells of embryonic neural crest origin, in particular, multifunctional immature dental pulp stem cells (IDPSCs). The invention discloses useful compositions and methods for the pre...  
WO/2019/213442A1
In certain aspects, the disclosure provides multispecific binders (e.g., ΑctRΙΙΑ:ΤβRII heteromultimers comprising an ActRlIA polypeptide and a TfiRU polypeptide). The disclosure further provides that such multispecific binders (e.g...  
WO/2019/210552A1
Provided are a neutralizing antibody against tetanus toxins, and a use thereof. The provided neutralizing antibody against tetanus toxins is capable of specifically binding to tetanus toxins, and thus has strong neutralizing activity and...  
WO/2019/210347A1
A method of treating muscular dystrophy in a subject or for improving muscle function or delaying decline in muscle function in a subject with muscular dystrophy comprising administering to the subject a pharmaceutical composition compri...  
WO/2019/211399A1
The present invention concerns a composition in the form of a micro- emulsion composed of (i) an oil phase comprising at least one omega 3 fatty acid or salt thereof and at least one glyceride, (ii) an aqueous phase and (iii) one or more...  
WO/2019/210377A1
Two synthetic tetrapeptides having a high binding affinity to human muscular nicotinic acetylcholine receptor (HmnAChR) are provided. A composition for inhibiting contraction of muscle cells is also provided. The composition comprises an...  
WO/2019/208627A1
The purpose of the present invention is to provide a composition, which comprises as an active ingredient a substance having an effect of preventing a decrease in muscle mass, preventing a decrease in muscular power, increasing muscle ma...  
WO/2019/205700A1
Disclosed in the present invention are an edaravone pharmaceutical composition and an application thereof as a sublingual preparation, the pharmaceutical composition containing edaravone or a salt thereof and mannitol. A sublingual admin...  
WO/2019/208968A1
The present invention relates to a pharmaceutical composition comprising dimenhydrinate, harmol, and/or calcium pantothenate for preventing or treating a muscular disease, wherein dimenhydrinate, harmol, and/or calcium pantothenate each ...  
WO/2019/205959A1
Disclosed are a pharmaceutical composition for treating epilepsy and convulsions, infantile convulsions and facial spasms and a preparation method therefor. The pharmaceutical composition comprises extracts of medicinal materials and aux...  

Matches 101 - 150 out of 26,205